Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Adjuvant specific immunotherapy in maintenance treatment of adult acute non-lymphocytic leukemia (1981)
    Springer
    Journal of molecular medicine 59 (1981), S. 1189-1193 
    Details
    ISSN: 1432-1440
    Keywords: Acute Leukemia ; Maintenance Therapy ; Specific Immunotherapy ; Akute Leukämie ; Erhaltungstherapie ; Spezifische Immuntherapie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Von 1976 bis 1978 wurden 136 erwachsene Patienten mit akuter Leukämie in vier Berliner Kliniken zytostatisch behandelt. Bei 47 Patienten (35%) konnte eine komplette Remission erzielt werden. Sechsundzwanzig Patienten mit kompletter Remission und einer akuten nicht-lymphatischen Leukämie, bei denen eine Induktionstherapie mit Daunorubidomycin (45 mg/m2/Tag, Tag 1, 2 und 3) und Cytosin-Arabinosid (100 mg/m2/Tag, Dauerinfusion, Tag 1 bis Tag 7) durchgeführt wurde, wurden in einer randomisierten Studie weiter behandelt. Dreizehn Patienten erhielten in vierwochigen Intervallen eine kombinierte Chemotherapie, die andere Gruppe erhielt zusätzlich eine spezifische Immuntherapie, die in der Injektion Neuraminidase-behandelter allogenetischer Blasten bestand. Die Ergebnisse zeigen, daß durch die zusätzliche Immuntherapie in der von uns durchgeführten Form keine Verlängerung der ersten Remission oder der Überlebenszeit erreicht werden konnte.
    Notes: Summary From 1976 until 1978, 136 adult patients with acute leukemia were treated in four hospitals in Berlin. A complete remission was achieved in 47 patients (35%). Twenty-six patients with non-lymphocytic acute leukemia, who had achieved a complete remission with induction chemotherapy consisting of daunorubicin (45 mg/m2/day, day 1, 2 and 3) and cytosine-arabinoside (100 mg/m2/day, continuous infusion, day 1 to day 7) were entered into a randomized trial. Thirteen patients were treated with an intermittent combination chemotherapy at 4-week intervals; the other group of patients received in addition a specific immunotherapy consisting of neuraminidase-modified allogeneic blast cells. The results revealed that the addition of this kind of immunotherapy did not increase the duration of first remission or survival.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01721213
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Besonders kleine Megakaryocyten bei chronisch myeloischer Leukämie, akuter Leukämie und Erythroleukämie (1974)
    Springer
    Journal of molecular medicine 52 (1974), S. 649-650 
    Details
    ISSN: 1432-1440
    Keywords: Megakaryocyte ; chronic myelocytic leukemia ; acute leukemia ; erythroleukemia ; Megakaryocyt ; chronisch myeloische Leukämie ; akute Leukämie ; Erythroleukämie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung In vereinzelten Fällen von chronisch myeloischer Leukämie, akuter Leukämie und Erythroleukämie wurden neben „Mikrokaryocyten“ noch kleinere Formen des megakaryocytären Systems unter 300µm2 im Knochenmark und teilweise im Blut gefunden. Mit Fortschreiten dieser Erkrankung nimmt die Anzahl dieser Zellen zu. Dem morphologischen Erscheinungsbild nach kann es sich um Degenerationsformen der „Mikrokaryocyten“ bzw. kleiner Megakaryocyten handeln.
    Notes: Summary Fifteen of 63 cases of chronic myelocytic leukemia, acute leukemia and erythroleukemia showed, in addition to microkaryocytes, another abnormal type of megakaryocytes which were smaller than 300µm2 and of different morphological appearance. These extremely small megakaryocytes appeared in 4 of 15 patients in the peripheral blood. The relative frequency of the cells increased with the progress of the disease. The morphologic appearance suggests that these cells are degenerative forms of microkaryocytes or of small megakaryocytes.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01468802
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Principles and present status of a prospective multicenter study on the clinical relevance of the kiel classification (1981)
    Springer
    Annals of hematology 43 (1981), S. 155-166 
    Details
    ISSN: 1432-0584
    Keywords: Non-Hodgkin lymphoma ; Kiel classification ; Low-grade malignancy ; High-grade malignancy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary On the basis of the retrospective analysis of 405 patients, suggesting the clinical relevance of the Kiel classification of non-Hodgkin lymphomas (NHL), a prospective multicenter study was started on October 1st, 1975, by the Kiel Lymphoma Study Group in order to further clarify the clinical and prognostic features of the different lymphoma entities defined by this histopathologic scheme. Diagnostic protocol provides initial staging evaluation according to a modification of the Ann Arbor classification. Therapeutic approach is based on the hypothesis that, like Hodgkin's disease, NHL originate, at least in part, as localized lymphatic or extralymphatic tumors. Thus, extended field irradiation is performed in stages I and II (except for lymphoblastic lymphoma in children and young adults) whereas in the more advanced stages III and IV (except for stage III of centroblastic-centrocytic lymphoma) chemotherapy with additional radiotherapy is applied. Until June 1979, 815 patients entered the study (69.7% with NHL of low-grade malignancy). For the interim evaluation underlying the present and the other papers of this series data of 511 patients were available. Survival of patients with NHL of low-grade malignancy significantly exceeds that of patients with NHL of high-grade malignancy. NHL with good prognosis such as chronic lymphocytic leukaemia and centroblastic-centrocytic lymphoma can be differentiated from NHL with a poor course such as lymphoblastic and immunoblastic lymphomas. In addition, the existence of a third group with an intermediate prognosis comprising centrocytic and centroblastic lymphomas and, possibly, also LP immunocytoma is suggested. However, different initial slope of survival curves shows that this latter group of NHL is not homogeneous with regard to prognosis.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00363886
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Germinal center cell lymphomas: Prognostic significance of their histopathological differentiation (1981)
    Springer
    Annals of hematology 43 (1981), S. 193-200 
    Details
    ISSN: 1432-0584
    Keywords: Non-Hodgkin lymphoma ; Centrocytic lymphoma ; Centroblastic-centrocytic lymphoma ; Centroblastic lymphoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Clinical data of 48 patients with centrocytic, 83 patients with centroblastic/centrocytic and 64 patients with centroblastic lymphoma who had entered a prospective multicenter study of the Kiel Lymphoma Study Group since October 1975 were compared. Advanced (stage IV) disease at time of diagnosis, predominantly due to bone marrow infiltration, was most frequent in centrocytic (69% of patients) and in centroblastic/centrocytic (51% of patients) lymphomas as compared to only 28% of patients with centroblastic lymphoma. High survival probability of patients with localized centrocytic and centroblastic/centrocytic lymphomas after radiotherapy, contrasting with a worse prognosis of corresponding patients with centroblastic lymphoma, is compatible with the classification of these lymphoma entities as neoplasias of low-grade malignancy. However, as shown by this prospective and previous retrospective trials overall survival probability of patients with advanced centrocytic lymphoma was inferior to that observed in corresponding patients with centroblastic/centrocytic lymphoma. These findings suggest the possibility that patients with advanced centrocytic lymphoma occupy an intermediate position between typical low-grade and typical high-grade malignant non-Hodgkin lymphomas.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00363889
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Lymphoplasmacytic/lymphoplasmacytoid lymphoma: A clinical entity distinct from chronic lymphocytic leukaemia? (1981)
    Springer
    Annals of hematology 43 (1981), S. 183-192 
    Details
    ISSN: 1432-0584
    Keywords: Non-Hodgkin lymphoma ; Chronic lymphocytic leukaemia ; Immunocytoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Clinical data of 116 patients with chronic lymphocytic leukaemia (CLL) and of 114 patients with lymphoplasmacytic/lymphoplasmacytoid lymphoma (synonym: LP immunocytoma, IC) as diagnosed according to the Kiel classification were compared. This interim evaluation of a prospective multicenter study of the Kiel Lymphoma Study Group characterizes IC the less favorable lymphoma entity as evidenced by a more rapid lymph node enlargement, by a higher incidence of constitutional symptoms and of marked anaemia, and by a higher percentage of patients requiring early treatment. In addition, in IC autoimmune haemolytic anaemia was detected in 11.2% of investigated patients as compared to none of the patients with CLL, and monoclonal gammopathy was disclosed in 34.2% of investigated patients as compared to only three patients with CLL who could be, however, unrecognized cases of IC. Actuarial survival data after a follow-up period of 40 months are in favor of an overall better prognosis of patients with CLL than of patients with IC.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00363888
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Clinical and prognostic heterogeneity of non-hodgkin lymphomas of high-grade malignancy (1981)
    Springer
    Annals of hematology 43 (1981), S. 201-211 
    Details
    ISSN: 1432-0584
    Keywords: Non-Hodgkin lymphoma ; High-grade malignancy ; Lymphoblastic lymphoma ; Immunoblastic lymphoma ; Centroblastic lymphoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Comparison of clinical data of 64 patients with centroblastic lymphoma, 55 patients with immunoblastic lymphoma and 31 patients with lymphoblastic lymphoma not only confirmed the original assumption of high-grade malignancy as proposed by the concept of the Kiel classification but also demonstrated distinct clinical differences, particularly between lymphoblastic lymphoma and the two other entities. Rapid lymph node enlargement as well as steep fall of survival curves within the first year after diagnosis were common characteristics. Bimodal age distribution, predominance of males and early generalization of disease were typical features of lymphoblastic lymphoma; elderly patients and patients with the unclassified subtypes of lymphoblastic lymphoma exhibited the worst prognosis. Whereas patients with centroblastic and immunoblastic lymphomas showed similar distribution of age, sex and initial stage of disease, patients with immunoblastic lymphoma presented more frequently with a reduced performance status and showed a poorer response to radio- and chemotherapy resulting in a worse prognosis discernible after the first year of follow-up. Generalization during course of the disease was significantly more frequent in immunoblastic than in centroblastic lymphoma.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00363890
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Myelomonozytäre Leukämie: Klinische, zytologische und zytogenetische Studien bei akuten, subakuten und chronischen Verlaufsformen (1977)
    Springer
    Annals of hematology 35 (1977), S. 21-34 
    Details
    ISSN: 1432-0584
    Keywords: Myelomonocytic ; Subacute and chronic leukemia ; Bone marrow cytogenetics and cytochemistry ; Lysozyme
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary 44 patients suffering from myelomonocytic leukemia (MML) have been observed over the last four years. They have been subclassified in acute myelomonocytic and acute monoblastic leukemias (AMML, n = 12; AMoL, n = 10), subacute myelomonocytic leukemias (SMML, n = 13), and chronic myelomonocytic leukemias (CMML, n = 9) on the basis of bone marrow cytology(blast and promonocyte counts, maturation of granulopoesis) and cytochemical findings (peroxydase and unspecific esterase reaction). This subclassification has been proved to be of prognostic relevance by its good correlation with the mean survival times (AMML: 4.5 months, AMoL: 2.4 months, SMML: 8 months, CMML: 18 months). The acute forms have been treated in general with combined cytostatic chemotherapy, whereas SMML and CMML have been treated this way only in case of progression to an acute phase. These progressions to an AMML have been observed more often and earlier in subacute forms than in chronic forms. The diagnosis of SMML and CMML is supported by the finding of sea-blue histiocytes in the bone marrow, increased lysozyme levels in serum and urine and by the absence of the Philadelphia-Chromosome.
    Notes: Zusammenfassung 44 Patienten mit myelomonozytärer Leukämie (MML) wurden während der letzten vier Jahre beobachtet. Eine Einteilung in akute myelomonozytäre und akute monoblastäre Leukämien (AMML, n = 12; AMoL, n = 10), subakute myelomonozytäre Leukämien (SMML, n = 13) und chronische myelomonozytäre Leukämien (CMML, n = 9) wurde aufgrund der Knochenmarkzytologie (Blasten- und Promonozytenanteil, Ausreifung der Granulopoese) und zytochemischer Befunde (Peroxydase- und unspezifische Esterase-Reaktion) vorgenommen. Diese Einteilung erwies sich als prognostisch relevant durch eine gute Korrelation mit den mittleren Überlebenszeiten (AMML: 4,5 Monate, AMoL: 2,4 Monate, SMML: 8 Monate, CMML: 18 Monate). Die akuten Verlaufsformen wurden in der Regel kombiniert zytostatisch behandelt, während SMML und CMML nur beim Übergang in eine akute Phase zytostatisch therapiert wurden. Derartige Übergänge in AMML wurden bei den subakuten Verlaufsformen häufiger und eher als bei den chronischen beobachtet. Zur Diagnose SMML, CMML trägt das Vorkommen seeblauer Histiozyten im Knochenmark, eine Lysozymerhöhung in Serum und Urin und das Fehlen des Philadelphia-Chromosoms bei.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01006961
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...